DelveInsight’s report titled “Neuroblastoma Pipeline Insight 2023” offers extensive information on more than 35+ companies and over 35+ pipeline drugs in the field of Neuroblastoma research. The Neuroblastoma pipeline report encompasses detailed profiles of the pipeline drugs for Neuroblastoma, including information on Neuroblastoma clinical trials and nonclinical stage products. It also provides a comprehensive assessment of the therapeutics based on product type, stage, route of administration, and molecule type. Additionally, the report highlights the inactive pipeline products in this domain.

 

For the Neuroblastoma emerging drugs, the pipeline analysis report presents a comprehensive view of the therapeutic landscape, considering the development stage, product type, route of administration, molecule type, and mechanism of action (MOA). The research on the Neuroblastoma pipeline covers various aspects such as business opportunities, challenges, potential partnerships, strong competitors, and growth strategies. It provides a detailed description of each drug, including its mechanism of action, Neuroblastoma clinical trial studies conducted for Neuroblastoma, any NDA approvals obtained for Neuroblastoma, and the product development activities encompassing technology, collaborations, licensing, mergers and acquisitions, funding, designations, and other relevant details.

 

To explore more information on the latest breakthroughs in the Neuroblastoma Pipeline treatment landscape of the report, click here @ Neuroblastoma Pipeline Outlook 

 

Key Takeaways from the Neuroblastoma Pipeline Report

• DelveInsight’s Neuroblastoma Pipeline analysis depicts a robust space with 35+ active players working to develop 35+ pipeline treatment therapies.
• The leading Neuroblastoma Companies are working in the market include Clarity Pharmaceuticals, Y mAbs Therapeutics, Nova Biopharma, Eli Lilly and Company, Illumina Radiopharmaceuticals, Recombio, United Therapeutics, Molecular Insight Pharmaceuticals, GE Healthcare, Millennium Pharmaceuticals, Genentech, Actuate Therapeutics, and others
• Emerging Neuroblastoma Pipeline Therapies in the various stages of development include APG-115, APG-2575, Topotecan, Temozolomide, Ribociclib, BCD-245, LY3295668 Erbumine, Cyclophosphamide, 18F-MFBG, UltratraceTM Iobenguane I 131 Imaging, Racotumomab, Dinutuximab Beta, 13 cis retinoic acid, and others
• On March, 2023, Ascentage Pharma Group Inc. announced drugs with name of APG-115 and APG-2575 by the phase 1. An open, non-randomized Phase I trial of dose-escalation and cohorts expansion to evaluate the safety, pharmacokinetic profile and initial efficacy of APG-115 alone or in combination with APG-2575 in the treatment of recurrent or refractory pediatric neuroblastoma or solid tumors.
• On May, 2023, Novartis Pharmaceuticals announced drugs with name of Topotecan, Temozolomide, Ribociclib by the phase 1 and 2. This is a Phase I/II study to assess the efficacy and safety of ribociclib in combination with topotecan and temozolomide (TOTEM) in pediatric patients with relapsed or refractory (r/r) neuroblastoma (NB), and other solid tumors, including medulloblastoma (MB), high-grade glioma (HGG), malignant rhabdoid tumors (MRT), and rhabdomyosarcoma (RMS).

 

Neuroblastoma Overview

Neuroblastoma is a highly malignant tumor in infants. However, it may also occur in children under 5 years of age. Neuroblastoma is composed of neuroblasts, usually in the medulla of an adrenal gland. However, it is possible for the tumor to form in the nerve tissue of the spinal cord, chest, or neck.

 

For further information, refer to the detailed Neuroblastoma Unmet Needs, Neuroblastoma Market Drivers, and Market Barriers, click here for Neuroblastoma Ongoing Clinical Trial Analysis

 

Neuroblastoma Emerging Drugs Profile

• 67Cu MeCOSar Octreotate : Clarity Pharmaceuticals
• Isotretinoin : Nova Laboratories
• AK 01 : Eli Lilly and Company

 

Neuroblastoma Pipeline Therapeutics Assessment

There are approx. 35+ Neuroblastoma companies which are developing the therapies for Neuroblastoma. The Neuroblastoma companies which have their Neuroblastoma drug candidates in the most advanced stage, i.e. Phase I/II, Clarity Pharmaceuticals.

 

Request a sample and discover the recent advances in Neuroblastoma Ongoing Clinical Trial Analysis and Medications, click here @ Neuroblastoma Treatment Landscape

 

Neuroblastoma Therapeutics Assessment

• Assessment by Stage and Product Type
• Assessment by Route of Administration
• Assessment by Stage and Route of Administration
• Assessment by Molecule Type
• Assessment by Stage and Molecule Type

 

Some of the Companies in the Neuroblastoma Therapeutics Market include-

Clarity Pharmaceuticals, Y mAbs Therapeutics, Nova Biopharma, Eli Lilly and Company, Illumina Radiopharmaceuticals, Recombio, United Therapeutics, Molecular Insight Pharmaceuticals, GE Healthcare, Millennium Pharmaceuticals, Genentech, Actuate Therapeutics, others.

 

Dive deep into rich insights for drugs for Neuroblastoma Pipeline, click here @ Neuroblastoma Unmet Needs and Analyst Views

 

Scope of the Neuroblastoma Pipeline Report

• Coverage- Global
• Neuroblastoma Companies- Clarity Pharmaceuticals, Y mAbs Therapeutics, Nova Biopharma, Eli Lilly and Company, Illumina Radiopharmaceuticals, Recombio, United Therapeutics, Molecular Insight Pharmaceuticals, GE Healthcare, Millennium Pharmaceuticals, Genentech, Actuate Therapeutics, and others.
• Neuroblastoma Therapies- APG-115, APG-2575, Topotecan, Temozolomide, Ribociclib, BCD-245, LY3295668 Erbumine, Cyclophosphamide, 18F-MFBG, UltratraceTM Iobenguane I 131 Imaging, Racotumomab, Dinutuximab Beta, 13 cis retinoic acid, and others.
• Neuroblastoma Segmentation: Product Type, Molecule Type, Route of Administration

 

Got Queries? Find out the related information on Neuroblastoma Mergers and acquisitions, Neuroblastoma Licensing Activities @ Neuroblastoma Emerging Drugs, and Recent Trends

 

Table of Content

1. Introduction
2. Neuroblastoma Executive Summary
3. Neuroblastoma: Overview
4. Neuroblastoma Pipeline Therapeutics
5. Neuroblastoma Therapeutic Assessment
6. Neuroblastoma– DelveInsight’s Analytical Perspective
7. Late Stage Neuroblastoma Products (Pre-Registration)
8. Drug Name : Company Name
9. Drug profiles in the detailed report…..
10. End Stage Neuroblastoma Products (Phase III)
11. Drug Name: Company Name
12. Drug profiles in the detailed report…..
13. Mid Stage Neuroblastoma Products (Phase I/ II)
14. Isotretinoin: Nova Laboratories
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. Drug Name: Company Name
18. Drug profiles in the detailed report…..
19. Inactive Neuroblastoma Products
20. Neuroblastoma Key Companies
21. Neuroblastoma Key Products
22. Neuroblastoma- Unmet Needs
23. Neuroblastoma- Market Drivers and Barriers
24. Neuroblastoma- Future Perspectives and Conclusion
25. Neuroblastoma Analyst Views
26. Neuroblastoma Key Companies
27. Appendix

 

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/case-study/respiratory-domain-conference-coverage